In vivo, a significant improvement in survival, a reduction (~89%) in tumor burden, and favorable modulation of the tumor microenvironment, characterized by a decrease in pro‐inflammatory cytokines (TNF‐α, IFN‐γ, IL‐6, VEGF) and an increase in IL‐10, was observed following treatment with arjunolic acid. The gene discussed is IL6; the disease is neoplasm.